0A4K Stock Overview
Provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Bionano Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.21 |
| 52 Week High | US$2.27 |
| 52 Week Low | US$0.20 |
| Beta | 2.38 |
| 11 Month Change | -25.01% |
| 3 Month Change | -59.85% |
| 1 Year Change | -87.14% |
| 33 Year Change | -99.46% |
| 5 Year Change | n/a |
| Change since IPO | -96.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A4K | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -12.9% | -10.6% | 0.8% |
| 1Y | -87.1% | -30.2% | 6.6% |
Return vs Industry: 0A4K underperformed the UK Life Sciences industry which returned -30.2% over the past year.
Return vs Market: 0A4K underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| 0A4K volatility | |
|---|---|
| 0A4K Average Weekly Movement | 11.1% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A4K's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A4K's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 344 | Robert Holmlin | www.bionano.com |
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.
Bionano Genomics, Inc. Fundamentals Summary
| 0A4K fundamental statistics | |
|---|---|
| Market cap | US$21.01m |
| Earnings (TTM) | -US$135.78m |
| Revenue (TTM) | US$33.33m |
0.6x
P/S Ratio-0.2x
P/E RatioIs 0A4K overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A4K income statement (TTM) | |
|---|---|
| Revenue | US$33.33m |
| Cost of Revenue | US$33.78m |
| Gross Profit | -US$442.00k |
| Other Expenses | US$135.34m |
| Earnings | -US$135.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.42 |
| Gross Margin | -1.33% |
| Net Profit Margin | -407.34% |
| Debt/Equity Ratio | 30.6% |
How did 0A4K perform over the long term?
See historical performance and comparison